Alzheimer'S Disease Research And Treatments
35 researchers across 5 institutions
Research in Alzheimer's disease and related dementias focuses on understanding the molecular and cellular mechanisms underlying neurodegeneration, with the goal of developing effective diagnostic tools and therapeutic interventions. Investigations explore the roles of protein aggregation, neuroinflammation, mitochondrial dysfunction, and genetic factors in disease progression. Studies employ a range of methodologies, including advanced imaging techniques, genetic analysis, biochemical assays, and preclinical models, to identify potential drug targets and assess treatment efficacy. This work also examines the impact of environmental exposures and metabolic disturbances on brain health.
This research holds significant relevance for Arkansas. As the state faces demographic shifts with an aging population, understanding and combating Alzheimer's disease is a critical public health priority. The insights gained can inform healthcare strategies and support the growing need for specialized elder care services. Furthermore, research into potential environmental contributors to neurodegenerative diseases can connect with the state's agricultural and industrial sectors, prompting investigations into the long-term health impacts of various exposures.
This area of study is inherently interdisciplinary, drawing upon expertise in neuroscience, pharmacology, genetics, biochemistry, and public health. Engagement spans multiple institutions across Arkansas, fostering collaboration and a comprehensive approach to tackling the complexities of Alzheimer's disease.
Top Researchers
| Name | Institution | h-index | Citations | Career Stage | Badges |
|---|---|---|---|---|---|
| W. Sue T. Griffin | UAMS | 65 | 17,454 | Grant PI High Impact | |
| Steven W. Barger | UAMS | 49 | 10,294 | Grant PI High Impact | |
| Philip Palade | UAMS | 39 | 5,103 | High Impact | |
| Sumit Sarkar | NCTR | 35 | 4,288 | High Impact | |
| Jiřı́ Novotný | University of Arkansas | 33 | 6,504 | High Impact | |
| Srinivas Ayyadevara | UAMS | 30 | 5,211 | High Impact Grants | |
| Ruby Charak | UAMS | 25 | 2,098 | ||
| Sharda P. Singh | UAMS | 25 | 2,600 | High Impact | |
| Meenakshisundaram Balasubramaniam | UAMS | 22 | 1,216 | High Impact | |
| Prabhash Nath Tripathi | UAMS | 20 | 1,673 | High Impact | |
| Chhanda Bose | UAMS | 20 | 1,078 | High Impact | |
| Héctor Rosas-Hernández | NCTR | 19 | 1,005 | ||
| Shitiz Sriwastava | UAMS | 19 | 1,883 | ||
| James Raymick | NCTR | 18 | 1,074 | ||
| Ning Nan | University of Arkansas | 18 | 1,515 | ||
| Asya Ozkızılcık | University of Arkansas | 17 | 508 | ||
| Milan Patel | Arkansas State University | 15 | 873 | ||
| Akshatha Ganne | UAMS | 10 | 274 | ||
| Rachel Hendrix | UAMS | 7 | 239 | ||
| Lewis Krain | UAMS | 7 | 341 |
Related Research Areas
Connected Research Areas
Topics that share active collaborators with Alzheimer'S Disease Research And Treatments in Arkansas. Pairs are ranked by collaboration density relative to expected co-authorship under a random null. This describes existing connections, not investment recommendations.
- Neuroscience and Neuropharmacology Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Dementia and Cognitive Impairment Research
- Neurological disorders and treatments
- Cancer Treatment and Pharmacology
- Aging and Longevity in Model Organisms
- Computational Drug Discovery Methods
- Gut microbiota and health
Strategic Outlook
Global signals from OpenAlex for this research area: where the field is growing, how concentrated leadership is, and where Arkansas sits relative to the world's top-100 institutions. Descriptive only — surfaced as input to the conversation about where to place bets, not a recommendation. Signal confidence: LOW
Top US institutions in this area
- 1 Harvard University 4,879
- 2 Massachusetts General Hospital 3,424
- 3 University of California, San Francisco 2,892
- 4 University of Pennsylvania 2,726
- 5 Washington University in St. Louis 2,670
Cross-Institution Connections
Researchers at different institutions with overlapping expertise in Alzheimer'S Disease Research And Treatments.